# Dynamics of T cell responses to COVID-19 vaccines and breakthrough infection in people living with HIV receiving antiretroviral therapy

- 3 4
- 5 Sneha Datwani<sup>1\*</sup>, Rebecca Kalikawe<sup>1\*</sup>, Rachel Waterworth<sup>1,3</sup>, Francis M. Mwimanzi<sup>1</sup>,
- 6 Richard Liang<sup>2</sup>, Yurou Sang<sup>1</sup>, Hope R. Lapointe<sup>2</sup>, Peter K. Cheung<sup>1,2</sup>, F. Harrison
- 7 Omondi<sup>1,2</sup>, Maggie C. Duncan<sup>1,2</sup>, Evan Barad<sup>1,2</sup>, Sarah Speckmaier<sup>2</sup>, Nadia Moran-
- 8 Garcia<sup>2</sup>, Mari L. DeMarco<sup>4,5</sup>, Malcolm Hedgcock<sup>6</sup>, Cecilia T. Costiniuk<sup>7</sup>, Mark Hull<sup>2,8</sup>,
- 9 Marianne Harris<sup>2,9</sup>, Marc G. Romney<sup>4,5</sup>, Julio S.G. Montaner<sup>2,8</sup>, Zabrina L. Brumme<sup>1,2</sup>#,
- 10 Mark A. Brockman<sup>1,2,3</sup>#
- 11
- <sup>1</sup>Faculty of Health Sciences, Simon Fraser University, Burnaby, Canada;
- <sup>2</sup> British Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada
- <sup>3</sup> Department of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby,
   Canada;
- <sup>4</sup> Department of Pathology and Laboratory Medicine, Providence Health Care,
   Vancouver, Canada;
- <sup>5</sup> Department of Pathology and Laboratory Medicine, University of British Columbia,
   Vancouver, Canada
- 20 <sup>6</sup> Spectrum Health, Vancouver, Canada
- 21<sup>7</sup> Division of Infectious Diseases and Chronic Viral Illness Service, McGill University
- 22 Health Centre and Research Institute of the McGill University Health Centre, Montreal,
- 23 Quebec, Canada
- <sup>8</sup>Department of Medicine, University of British Columbia, Vancouver, Canada;
- <sup>9</sup>Department of Family Practice, Faculty of Medicine, University of British Columbia,
   Canada
- 27
- 28 \*equal contribution
- 29 #Corresponding authors: MAB, mark\_brockman@sfu.ca; ZLB, zbrumme@sfu.ca
- 30
- 31 Abstract: 349 words
- 32 Text: 4,102 words
- 33 Inserts: 5 (1 Table, 4 Figures)
- 34 Supplemental files: 5 (2 Supplemental Figures, 3 Supplemental Tables)
- 35
- 36 Keywords: Covid-19, SARS-CoV-2, coronavirus, vaccine, T cells, HIV, antiretroviral
- 37 therapy
- 38

### 39 **ABSTRACT** (349 words)

40	Introduction: People living with HIV (PLWH) can exhibit impaired immune responses
41	to vaccines. Accumulating evidence indicates that PLWH, particularly those receiving
42	antiretroviral therapy, mount strong antibody responses to COVID-19 vaccination, but
43	fewer studies have examined cellular immune responses to vaccination. We measured
44	SARS-CoV-2 spike-specific CD4+ and CD8+ T cell responses generated by two and
45	three doses of COVID-19 vaccine in PLWH receiving antiretroviral therapy, compared to
46	control participants without HIV. We also quantified T cell responses after post-vaccine
47	breakthrough infection, and receipt of fourth vaccine doses, in a subset of PLWH.
48	
49	Methods: We quantified CD4+ and CD8+ T cells reactive to overlapping peptides
50	spanning the ancestral SARS-CoV-2 spike protein in 50 PLWH and 87 controls without
51	HIV, using an activation induced marker (AIM) assay. All participants remained SARS-
52	CoV-2 naïve until at least one month after their third vaccine dose. SARS-CoV-2
53	infection was determined by seroconversion to nucleocapsid (N) antigen, which occurred
54	in 21 PLWH and 38 controls post-third dose. Multivariable regression analyses were used
55	to investigate relationships between sociodemographic, health and vaccine-related
56	variables and vaccine-induced T cell responses, as well as breakthrough infection risk.
57	
58	<b>Results:</b> A third vaccine dose boosted spike-specific CD4+ and CD8+ T cell frequencies
59	significantly above those measured after the second dose (all p<0.0001). Median T cell
60	frequencies did not differ between PLWH and controls after the second dose (p>0.1), but
61	CD8+ T cell responses were modestly lower in PLWH after the third dose (p=0.02), an

62	observation that remained significant after adjustment for sociodemographic, health and
63	vaccine-related variables (p=0.045). In PLWH who experienced breakthrough infection,
64	median T cell frequencies increased even higher than those observed after three vaccine
65	doses (p<0.03), and CD8+ T cell responses in this group remained higher even after a
66	fourth vaccine dose (p=0.03). In multivariable analysis, the only factor associated with
67	increased breakthrough infection risk was younger age, consistent with the rapid
68	increases in SARS-CoV-2 seropositivity among younger adults in Canada after the initial
69	appearance of the Omicron variant.
70	

- 71 Conclusion: PLWH receiving antiretroviral therapy mount strong T cell responses to
- 72 COVID-19 vaccines that can be enhanced by booster doses or breakthrough infection.

## 73 INTRODUCTION

74	Prior to the widespread availability of COVID-19 vaccines, there was evidence
75	that people living with HIV (PLWH) were at increased risk of severe COVID-19
76	outcomes [1-5], making vaccination particularly important in this group. Since then, a
77	growing body of evidence indicates that COVID-19 vaccines have been highly effective
78	at preventing severe disease associated with SARS-CoV-2 infection, including in PLWH
79	[6, 7]. Studies analyzing vaccine-induced immune responses, including from our group,
80	also confirm that PLWH, in particular those who are receiving suppressive antiretroviral
81	therapy, mount robust humoral (antibody) response to COVID-19 immunization [8-16].
82	But comparably fewer studies have investigated the cellular immune response to COVID-
83	19 vaccines in PLWH, which includes CD4+ helper T cells that play a central role in
84	generating antigen-specific B cells and antibodies and CD8+ cytotoxic T cells that
85	recognize and eliminate virus-infected cells [17-20]. Indeed, while COVID-19 vaccines
86	typically induce strong T cell responses [21, 22], the frequency of spike-specific CD4+ T
87	cells following COVID-19 vaccination may be lower in PLWH, in particularly among
88	those with low CD4+ T cell counts [9, 23]. A better understanding of T cell responses
89	elicited by COVID-19 vaccines, as well as breakthrough SARS-CoV-2 infections, will
90	inform ongoing efforts to enhance protective immunity in PLWH.
91	Towards this goal, we investigated the dynamics of spike-specific CD4+ and
92	CD8+ T cell responses elicited after two and three doses of COVID-19 vaccine in a
93	cohort of 50 adult PLWH receiving antiretroviral therapy, and 87 controls without HIV.
94	All participants remained naïve to SARS-CoV-2 until at least one month after their third
95	dose. We additionally investigated spike-specific CD4+ and CD8+ T cell responses in a

96	subset of 21 PLWH who experienced their first SARS-CoV-2 breakthrough infection
97	between one and six months after their third vaccine dose. Overall, our results revealed
98	that spike-specific CD4+ and CD8+ T cell frequencies were boosted with each vaccine
99	dose, and that these responses were broadly comparable between PLWH and controls,
100	with the exception of CD8+ T cell responses after the third dose, which were moderately
101	lower in PLWH compared to controls. Breakthrough infection further boosted median
102	spike-specific T cell frequencies, and CD8+ T cell responses remained higher in these
103	individuals even after a fourth vaccine dose.
104	
105	METHODS
106	Participants. Our cohort of COVID-19 vaccine recipients, based in British Columbia
107	(BC) Canada, has been described previously [10, 13, 24]. Of the 99 PLWH and 152
108	controls (without HIV) originally enrolled in the study, 62 (PLWH) and 117 (controls)
109	remained naïve for SARS-CoV-2 infection until at least one month after their third
110	COVID-19 vaccine dose. Of these, we examined a subset of 50 PLWH and 87 controls,
111	selected largely based on sample availability (Table 1).
112	
113	Ethics approval. Written informed consent was obtained from all participants. This study
114	was approved by the University of British Columbia/Providence Health Care and Simon
115	Fraser University Research Ethics Boards.
116	
117	SARS-CoV-2 seroconversion. SARS-CoV-2 infection was identified based on the
118	development of serum antibodies against the viral Nucleocapsid (N) protein using the

- 119 Elecsys Anti-SARS-CoV-2 assay (Roche Diagnostics), combined with diagnostic (PCR-
- 120 and/or rapid-antigen-test) information where available.
- 121
- 122 *T cell activation induced marker assays.* Cryopreserved peripheral blood mononuclear
- 123 cells (PBMC) were thawed and diluted in TexMACS media (Miltenyi Biotec, Cat#130-
- 124 097-196). PBMC were stimulated at  $1 \times 10^6$  cells per well for 24 hours with peptide pools
- spanning the SARS-CoV-2 ancestral spike protein (15-mers, overlapping by 11 amino
- acids) (Miltenyi Biotec, Cat#130-127-953) in duplicate in a 96-well U-bottom plate.
- 127 PBMC were incubated with media only (no peptide) as a negative control or 2 µg/ml
- 128 CytoStim reagent (Miltenyi Biotec, Cat#130-092-172) as a positive control. Following
- stimulation, cells were labeled with CD8-APC/Cyanine7 (Biolegend, Cat#301016), CD4-
- 130 FITC (Biolegend, Cat#300538), CD137-APC (Biolegend, Cat#309810), CD69-PE (BD,
- 131 Cat#555531), OX40-PE-Cy7 (Biolegend, Cat#350012), CD3-PerCP/Cyanine5.5
- 132 (Biolegend, Cat#317336) CD14-V500 (BD, Cat#561391), CD19-V500 (BD,
- 133 Cat#561121) and 7-AAD Viability Staining Solution (Biolegend, Cat#420404). Data
- 134 were acquired on a Beckman Coulter Cytoflex S flow cytometer, with a minimum of
- 135 10,000 CD3+ T cells assayed per participant. After identifying CD3+CD4+ and
- 136 CD3+CD8+ T cell subsets, the percentage of stimulated cells was determined based on
- 137 upregulation of two activation markers, using CD137 and OX40 for CD4+ T cells, and
- 138 CD137 and CD69 for CD8+ T cells (see gating strategy in Figure S1). Data were
- analyzed in FlowJo version 10.8.1.
- 140

*SARS-CoV-2 neutralization.* We previously reported the ability of participant plasma to
neutralize ancestral SARS-CoV-2 (isolate USA-WA1/2020; BEI Resources, Cat #NR52281), based on the results of a live-virus assay [24].

144

145 Statistical analyses. Continuous variables were compared using the Mann-Whitney U-146 test (for unpaired data) or Wilcoxon test (for paired measures). Relationships between 147 continuous variables were assessed using Spearman's correlation. Zero-inflated beta 148 regressions were used to investigate the relationship between sociodemographic factors 149 and vaccine-induced T cell responses using a confounder model that adjusted for 150 variables that could influence these responses, or that differed in prevalence between 151 groups. These regressions model the response variable as a beta-distributed random 152 variable whose mean is given by a linear combination of the predictor variables (after a 153 logit transformation). Beta distributions are bounded below and above by 0 and 100%, 154 making this a standard choice of regression for frequency data. Because a beta 155 distribution does not admit values of 0 (or 100), we used a zero-inflated beta distribution, 156 which allows for zeros in the data, to accommodate the minority of non-responders (*i.e.* 0 157 values) in our data. For analyses performed after two-dose vaccination, included 158 variables were: HIV status (non-PLWH as reference), age (per year), sex at birth (female 159 as reference), ethnicity (non-white as reference), chronic conditions (per condition), 160 ChAdOx1-containing initial vaccine regimen (mRNA only vaccination as reference) and 161 the interval between first and second doses (per day). Analyses performed after three-162 dose vaccination also included the third COVID-19 mRNA dose brand (BNT162b2 as 163 reference), the interval between second and third doses (per day), and the % spike-

164 specific T cells after two doses (per percent increase). Multivariable logistic regression 165 was used to explore the relationship between these same variables and the risk of SARS-166 CoV-2 breakthrough infection between one and six months after the third vaccine dose. 167 All tests were two-tailed, with p<0.05 considered statistically significant. Analyses were 168 conducted using Prism v9.2.0 (GraphPad) and in R. 169 170 RESULTS 171 **Participant characteristics** 172 Characteristics of the 50 PLWH and 87 controls without HIV are shown in Table 173 1. All participants remained COVID-19 naïve until at least one month after their third 174 vaccine dose, as confirmed by repeated negative serology for SARS-CoV-2 anti-N 175 antibodies, and lack of reporting of any SARS-CoV-2 positive test result (either by PCR 176 or rapid antigen test), up to this time point. PLWH and controls were a median age of 58 177 (interquartile range [IQR] 42-65) and 50 (IQR 35-72) years old, respectively, and 178 predominantly of white ethnicity (72% of PLWH and 57% of controls). Most PLWH 179 were male (88%, reflecting the overall population of PLWH in BC), while most controls 180 were female (67%, broadly reflecting the overall demographics of health care workers in 181 the region, from which the controls were predominantly recruited). Both groups reported 182 few chronic health conditions (excluding HIV infection; median 1 [IQR 0-1] in PLWH, 183 versus median 0 [IQR 0-1] in controls). All PLWH were receiving combination 184 antiretroviral therapy, with a median HIV plasma viral load of <50 copies/mL (IQR <50 -185 <50 copies/mL) at study entry. The median CD4+ T cell count at study entry among

PLWH was 695 (IQR 468-983) cells per mm<sup>3</sup>, while median nadir CD4+ T cell count
was 250 (IQR 140-490) cells per mm<sup>3</sup>.

188 Most participants (84% of PLWH and 97% of controls) initially received two 189 doses of mRNA vaccine, either BNT162b2 or mRNA-1273; the remainder received at 190 least one ChAdOx1 dose in their initial series. In PLWH, second vaccine doses were 191 administered a median of 59 days after the first, compared to an median interval of 89 192 days in controls (p<0.0001). This is because Canada delayed second doses well beyond 193 the manufacturers' recommended 21-28 day interval, due to initially limited availability 194 of vaccine supplies in the country [25]. As a result, individuals who received their first 195 doses early in the vaccination campaign, including most health care workers, generally 196 waited the longest to receive their second doses. Retrospectively, it was determined that 197 delaying second doses did not reduce vaccine efficacy, and in some cases may have 198 enhanced protection [26] and reduced the risk of myocarditis [27], prompting the World 199 Health Organization to recommend a 2-month (~60-day) interval between first and 200 second doses [28]. As a result, our multivariable analyses adjust for between-dose 201 intervals and other sociodemographic and clinical attributes listed in Table 1. Third 202 vaccine doses were predominantly mRNA-1273 (66% of PLWH and 61% of controls) 203 and were administered a median of 182 to 197 days (approximately 6 to 6.5 months) after 204 the second dose. Third mRNA-1273 dose amounts also differed by age and health 205 history: according to vaccine guidelines in British Columbia, adults 65 years of age and 206 older, as well as PLWH with a history of immunodeficiency, were eligible for a 100 mcg 207 dose whereas all others were eligible for a 50 mcg booster dose (all BNT162b2 doses 208 were 30 mcg). A total of 21 (42%) of PLWH and 38 (44%) of controls experienced their

209 first SARS-CoV-2 infection between one and six months after the third vaccine dose, as

210 determined by seroconversion to the SARS-CoV-2 N protein and/or self-reported positive

211 SARS-CoV-2 test results where available. Though viral genotyping was not performed

212 for these "breakthrough" infections, these were likely Omicron BA.1 or BA.2 based on

- 213 local molecular epidemiology trends at the time [29].
- 214

### 215 T cell responses following two and three COVID-19 vaccine doses

216 Prior to vaccination, the percentage of spike-specific CD4+ and CD8+ T cells,

217 measured in a subset of 10 PLWH and 15 controls, was negligible as expected (Figures

**1A, 1B**). Following two vaccine doses, the percentage of spike-specific CD4+ T cells

219 increased significantly from pre-vaccine levels (paired measures p≤0.004 for both PLWH

and controls), reaching a median 0.25% (IQR 0.07-0.50) in PLWH and a median 0.32%

221 (IQR 0.15-0.55) in controls, a difference that was not statistically significant between

groups (p=0.11; Figure 1A). CD8+ T cell responses also increased significantly from

pre-vaccine levels following two vaccine doses (paired measures  $p \le 0.002$  in both

groups), reaching a median 0.39% (IQR 0.22-0.53) in PLWH and a median 0.31% (IQR

225 0.14-0.61) in controls, a difference that was not statistically significant between groups

226 (p=0.39; Figure 1B). The lack of statistically significant differences in vaccine-induced T

227 cell responses between PLWH and controls remained after controlling for socio-

228 demographic, health and vaccine-related variables (p=0.08 for CD4+ T cell responses;

229 p=0.99 for CD8+ T cell responses; Tables S1 and S2). Of note, these multivariable

analyses did not identify any variables that were significantly associated with spike-

231 specific CD4+ T cell responses after two vaccine doses (Table S1), though having

received at least one ChAdOx1 dose as part of the initial vaccine series was weakly
associated with higher spike-specific CD8+ T cell responses after the second vaccine
dose (p=0.049; Table S2).

235	A third vaccine dose further boosted the percentage of spike-specific CD4+ T
236	cells beyond the levels observed after two doses (paired measures p<0.0001 for both
237	PLWH and controls; Figure 1A). After the third dose, spike-specific CD4+ T cell
238	frequencies reached a median 0.67% (IQR 0.50-0.86) in PLWH compared to a median
239	0.71% (IQR 0.40-0.98) in controls (p=0.52; Figure 1A), where this lack of significant
240	difference between groups remained after controlling for sociodemographic, health and
241	vaccine-related variables (p=0.58; Table S1). Similarly, a third vaccine dose further
242	boosted the percentage of spike-specific CD8+ T cells (paired measures p<0.0001 for
243	both groups; Figure 1B). Somewhat in contrast to the other immune measures however,
244	the median CD8+ T cell response in PLWH (0.61%; IQR 0.43-0.79) was lower compared
245	to that of controls (0.78%; IQR 0.43-1.1) after the third vaccine dose (p=0.02; Figure
246	<b>1B</b> ). This difference remained marginally statistically significant after controlling for
247	sociodemographic, health and vaccine-related variables (p=0.045; Table S2).
248	The multivariable analyses also revealed that by far the strongest predictors of
249	spike-specific CD4+ and CD8+ T cell responses after three vaccine doses were the
250	corresponding percentage of spike-specific T cells achieved after two doses (Tables S1,
251	S2). For example, the zero-inflated beta regression estimates for the impact of each $1\%$
252	increment in post-second dose T cell frequencies on post-third dose frequencies were
253	0.71 for CD4+ T cells ( $p \le 2 \times 10^{-16}$ ) and 0.79 for CD8+ T cells ( $p \le 2 \times 10^{-16}$ ). To interpret
254	these estimates: if the value of the linear predictor was x for a given set of values of the

255	predictors, and the % of spike-specific CD4+ T cells after two vaccine doses was
256	increased by 1%, the resulting value of the linear predictor would now be $x + 0.71$ , which
257	translates to a non-linear increase in the regressed mean from 100*logit(x) to 100*logit(x
258	+ 0.71), where the factor of 100 converts the proportions to percentages. Male sex,
259	receipt of an mRNA-1273 booster, and, somewhat unexpectedly, a higher number of
260	chronic health conditions, were also independently associated with higher spike-specific
261	CD4+ T cell responses (estimates 0.11 - 0.24; all p<0.04; Table S1). We hypothesize that
262	the association between chronic health conditions and better T cell responses is because,
263	after adjusting for post-second-dose responses, individuals with such conditions benefited
264	particularly from a third dose. The association with mRNA-1273 is likely because adults
265	aged 65 years and older, as well as PLWH with a history of immune dysfunction were
266	eligible for the higher (100mcg) mRNA-1273 third dose in British Columbia, whereas the
267	general population received the standard 50 mcg booster dose.
268	

### 269 Correlations between vaccine-induced T cell responses and other immune measures

270 The percentages of spike-specific CD4+ and CD8+ T cells were strongly 271 associated with one another after the second vaccine dose (Spearman's  $\rho=0.57$ ; p<0.0001) 272 as well as after the third dose (Spearman's  $\rho=0.54$ ; p<0.0001; **Figure 2A**). No association 273 was observed between the percentage of spike-specific CD4+ T cells and the magnitude 274 of vaccine-induced neutralizing antibody responses based on a live-virus assay (reported 275 previously by our group [24]) after either the second (Spearman's  $\rho=-0.04$ , p=0.7) or third 276 dose (Spearman's  $\rho=-0.07$ , p=0.4; **Figure 2B**). Prior studies have linked the frequency of

277 CD4+ T follicular helper cells with antibody responses [30], but we did not assess T cell
278 subsets here.

279	As CD4+ T cell counts are used as an indicator of immune function in PLWH, we
280	evaluated the relationship between this parameter and vaccine-induced T cell responses
281	in this group. We observed no association between the most recent CD4+ T cell count
282	and the frequency of either spike-specific CD4+ or CD8+ T cells following the second or
283	third vaccine doses (Spearman's $\rho$ =-0.09 to -0.18; all p>0.2; Figure S2). Similarly, we
284	observed no association between nadir CD4+ T cell counts and vaccine-induced CD4+ T
285	cell responses after either dose (Spearman's $\rho$ =-0.05 and -0.12, respectively, both p>0.4)
286	(Figure S2). By contrast, an unexpected modest negative correlation was found between
287	nadir CD4+ T cell counts and spike-specific CD8+ T cell responses after both the second
288	(Spearman's $\rho$ =-0.29, p=0.04) and third (Spearman's $\rho$ =-0.28, p=0.05) dose. We
289	hypothesize that the post-third-dose results are because PLWH with a history of immune
290	dysfunction were eligible for a higher (100 mcg) third dose of mRNA-1273, though this
291	would not explain our post-second-dose results. Regardless, there is no indication that a
292	low nadir CD4+ count impaired T cell responses to COVID-19 vaccination in our cohort.
293	

### 294 Breakthrough infection further boosts CD4+ and CD8+ T cell responses

In British Columbia, the initial waves of Omicron BA.1 and BA.2 occurred after the mass administration of third vaccine doses in the province. Of the 50 PLWH studied, 21 (42%) PLWH experienced SARS-CoV-2 breakthrough infections between 1 and 6 months following their third dose. Post-breakthrough plasma and PBMC specimens were available from nearly all PLWH, so we further examined humoral (neutralizing antibody)

300	and cellular immune responses 6 months after the third dose, and again one month after
301	receipt of a fourth vaccine dose, in the PLWH cohort (n=50) (Figure 3). As we reported
302	previously [12, 24], plasma neutralizing antibody activity declined significantly among
303	SARS-CoV-2-naïve individuals after the third vaccine dose, but in those who
304	experienced breakthrough infection, neutralization activity increased to above peak levels
305	induced by vaccination. For example, at 6 months post-third vaccine dose, the median
306	virus neutralization titer (reported as a reciprocal dilution) was 640 (IQR 320-2560) in
307	PLWH who experienced a breakthrough infection, double the observed value in this
308	group after three vaccine doses alone (paired test, p=0.002; Figure 3A). This
309	neutralization titer was also eight times higher than the median titer of 80 (IQR 20-160)
310	observed at 6 months post-third vaccine dose in PLWH who remained SARS-CoV-2
311	naïve (p<0.0001; Figure 3A). The observation that neutralization titers increase
312	significantly following breakthrough infection confirms the ongoing presence of spike-
313	specific memory B cells despite diminished neutralizing activity in blood.
314	In contrast to neutralizing antibodies, spike-specific CD4+ and CD8+ T cell
315	frequencies did not wane in SARS-CoV-2 naïve PLWH following vaccination. In fact,
316	the percentage of both spike-specific CD4+ and CD8+ T cells increased slightly between
317	1 and 6 months after the third vaccine dose (paired p=0.003 and p=0.005 respectively,
318	Figures 3B and 3C), consistent with the continued presence of vaccine-induced T cells
319	even in the absence of antigen. Like humoral responses however, breakthrough infection
320	boosted T cell responses to levels higher than those observed in the same participants
321	after vaccination alone (both paired tests $p \le 0.0001$ ; Figures 3B and 3C). Moreover, the
322	median percentage of spike-specific CD4+ T cells at 6 months post-third vaccine dose in

323	breakthrough cases was a 1.01% (IQR 0.78-1.51), compared to 0.70% (IQR 0.60-1.02) in
324	SARS-CoV-2- naïve participants at this same time point (p=0.03; Figure 3B), while the
325	median percentage of spike-specific CD8+ T cells in breakthrough cases was 1.20% (IQR
326	0.96-1.55), compared to 0.80% (IQR 0.60-1.02) in SARS-CoV-2 naïve participants at
327	this time point (p=0.002; Figure 3C).
328	A fourth vaccine dose significantly increased neutralizing antibody responses and
329	spike-specific T cell responses in SARS-CoV-2 naïve PLWH (all paired tests p≤0.0001;
330	Figures 3A, 3B, 3C), illustrating the immune benefit of a fourth vaccine dose in the
331	absence of SARS-CoV-2 infection. A fourth dose also significantly increased humoral
332	and cellular immune responses in PLWH who experienced prior breakthrough infection
333	(all paired tests p<0.03; Figures 3A, 3B, 3C). Of note, post-fourth dose neutralizing
334	antibody titers and CD8+ T cell responses in PLWH who experienced breakthrough
335	infection were significantly higher than among SARS-CoV-2 naïve PLWH at this same
336	time (p=0.001 and p=0.03 respectively; Figures 3A and 3C), consistent with prior
337	reports of superior "hybrid" immunity generated by a combination of vaccination and
338	infection [31, 32].
339	

### 340 Correlates of protection against breakthrough infection

341 Given the substantial proportion of participants who experienced their first SARS-

342 CoV-2 breakthrough infection between one and six months following three-dose

343 vaccination (42% of PLWH; 44% of controls), we explored our data for potential

344 correlates of protection. As HIV status was not associated with breakthrough infection

345 (p=0.86), PLWH and control groups were combined for analysis, yielding 78 participants

346	who remained SARS-CoV-2 naïve and 59 participants who experienced SARS-CoV-2
347	infection during the follow-up period. Univariable analyses revealed older age to be
348	significantly associated with protection against breakthrough infection: participants
349	remaining SARS-CoV-2 naïve were a median 60 [IQR 42-71] years old while those who
350	experienced breakthrough infection were a median 43 [IQR 34-60] years old (combined
351	cohort p=0.001; Figure 4A). This observation was largely driven by the control group,
352	which included 29 adults age 70 years or over (compared to 3 in the PLWH group). The
353	percentage of spike-specific CD4+ T cells one month after the third vaccine dose was not
354	associated with breakthrough infection (p=0.72 for the combined cohort; Figure 4B), but
355	a higher percentage of spike-specific CD8+ T cells at this time point was associated with
356	remaining SARS-CoV-2 naïve (p=0.046 for the combined cohort) (Figure 4C). This
357	observation was driven by differences in CD8+ T cell responses among PLWH (p=0.02)
358	and suggests that cytotoxic T cells specific for SARS-CoV-2 may contribute to
359	protection. Somewhat surprisingly, we found no association between neutralizing
360	antibody responses induced by three vaccine doses and breakthrough infections (p=0.33
361	for the combined cohort) (Figure 4D), likely because vaccine-induced antibodies against
362	the ancestral (Wuhan) spike had limited activity against the Omicron strains that caused
363	the majority of breakthrough infections, and because these infections occurred a median
364	of 3.7 months after booster vaccination, when circulating antibody titers had declined
365	substantially. In a multivariable logistic regression analysis that incorporated participant
366	sociodemographic, vaccine and immune response variables, older age was the only
367	significant predictor of protection against SARS-CoV-2 breakthrough infection (Table
368	<b>S3</b> ). Though at first surprising, this observation is consistent with the very rapid rise in

369	SARS-CoV-2 anti-N seroprevalence in Canada among younger individuals following the
370	emergence of Omicron, and likely reflects the impact of social/behavioural factors rather
371	than biological factors. For example, by mid-June 2022, anti-N seroprevalence in
372	Canadian adults aged < 25 years was 57%, in those aged 25–39 years it was 51%, in
373	those aged 40–59 years it was 40%, and in those 60 years or older it was 25% [33].
374	Similar age-specific trends were observed in Finland [34] and the USA [35], suggesting
375	that many older adults continued to benefit from efforts to limit exposure to COVID-19
376	in the community, even after the arrival of Omicron.

377

### 378 **DISCUSSION**

379 We observed that the frequencies of SARS-CoV-2 spike-specific CD4+ and 380 CD8+ T cells were not significantly different between PLWH and controls after two 381 doses of COVID-19 vaccine. Both CD4+ and CD8+ T cell responses were enhanced 382 following a third vaccine dose, but the frequency of spike-specific CD8+ T cells was 383 modestly lower in PLWH compared to controls. PLWH generated robust spike-specific T 384 cell responses following post-vaccine breakthrough infection, reaching levels that were 385 equivalent to those achieved after a fourth vaccine dose in SARS-CoV-2 naïve PLWH. 386 Of note, receiving a fourth vaccine dose after having experienced a breakthrough SARS-387 CoV-2 infection enhanced immune responses even further, with neutralizing antibody 388 responses and CD8+ T cell responses reaching levels significantly higher than those 389 observed in SARS-CoV-2 naïve individuals after four doses. This finding is consistent 390 with previous reports describing the superiority of "hybrid" immunity generated through 391 a combination of vaccination and infection [31, 32].

392	Our results are broadly consistent with other recent studies showing that vaccine-
393	induced spike-specific T cell responses are equivalent in PLWH and controls without
394	HIV, particularly among PLWH receiving antiretroviral therapy [9, 17-20, 23]. We found
395	no association between CD4+ T cell responses and neutralizing antibodies after either
396	two or three vaccine doses, suggesting that sufficient T cell help was provided to
397	stimulate spike-specific B cell responses despite a wide range of antigen-specific CD4+ T
398	cell frequencies induced by vaccination. While our results do not rule out potential
399	dysfunction in vaccine-induced T cells among PLWH, our data suggest that the impact of
400	T cell impairment is likely to be modest after the second and third vaccine dose.
401	This study has some limitations. All PLWH were receiving suppressive
402	antiretroviral therapy and had generally preserved CD4+ T cell counts, so our
403	observations may not be generalizable to PLWH who have low CD4+ T cell counts or
404	untreated HIV. Since this was an observational study, PLWH and control participants
405	were not matched at enrolment. Though we included known variables in multivariable
406	regression analyses, residual effects of variables that differed between groups (e.g. sex,
407	vaccine regimen type) or other unknown factors could influence our results. We also
408	lacked information on the concentration of mRNA-1273 third doses (100 mcg versus 50
409	mcg), and therefore we could not investigate the impact of this on immune responses.
410	While the activation induced marker assay provides a sensitive method to quantify spike-
411	specific CD4+ and CD8+ T cells, we did not analyze T cell subsets such as follicular
412	helper cells, nor T cell functions such as cytokine production or proliferation, that could
413	reveal differences in the effector activity of vaccine- or infection-induced responses.
414	Finally, since T cell responses were measured using peptide pools spanning only the

415 ancestral spike protein, we cannot comment on the relative dominance of individual T 416 cell epitopes nor on potential changes in the distribution of T cell responses following 417 repeated vaccination or breakthrough infection.

418

#### 419 CONCLUSIONS

- 420 In summary, our study indicates that PLWH who are receiving suppressive
- 421 antiretroviral therapy mount strong CD4+ and CD8+ T cell responses to COVID-19
- 422 vaccines that are comparable to those found in individuals without HIV. Repeated
- 423 exposure to SARS-CoV-2 spike antigen, either through vaccination or infection, further
- 424 enhanced T cell responses in PLWH. PLWH status was not associated with increased risk
- 425 of post-vaccine breakthrough infection in our cohort, but older age was found to be a
- 426 significant predictor of protection against infection, consistent with lower SARS-CoV-2
- 427 anti-N seropositivity rates among older adults in Canada following the emergence of
- 428 Omicron [33]. These results further underscore the benefits of COVID-19 vaccination in
- 429 PLWH.

430

#### 431 **DECLARATIONS**

#### 432 Ethics approval and consent to participate

Fraser University Research Ethics Boards.

433 Written informed consent was obtained from all participants. This study was 434 approved by the University of British Columbia/Providence Health Care and Simon 435

436

#### 437 **Consent for publication**

438	Not applicable.
439	
440	Availability of data and materials
441	The datasets analysed in this study are available from the corresponding author
442	upon reasonable request. Data have also been deposited into the COVID-19 Immunology
443	Task Force (CITF) data bank (https://portal.citf.mcgill.ca/).
444	
445	Competing interests
446	The authors declare that they have no competing interests.
447	
448	Funding
449	This work was supported by the Public Health Agency of Canada through a
450	COVID-19 Immunology Task Force COVID-19 "Hot Spots" Award (2020-HQ-000120
451	to MGR, ZLB, MAB). Additional funding was received from the Canadian Institutes for
452	Health Research (GA2-177713 to MAB), the Coronavirus Variants Rapid Response
453	Network (FRN-175622 to MAB), the Canada Foundation for Innovation through
454	Exceptional Opportunities Fund – COVID-19 awards (to MAB, MLD, ZLB). FMM was
455	supported by fellowships from the Canadian Institutes of Health Research (CIHR)
456	Canadian HIV Trials Network and Michael Smith Health Research BC (MSHR-BC).
457	FHO was supported by a Ph.D. fellowship from the Sub-Saharan African Network for
458	TB/HIV Research Excellence (SANTHE), a DELTAS Africa Initiative (grant # DEL-15-
459	006). The DELTAS Africa Initiative is an independent funding scheme of the African
460	Academy of Sciences (AAS)'s Alliance for Accelerating Excellence in Science in Africa

461 (AESA) and supported by the New Partnership for Africa's Development Planning and

462 Coordinating Agency (NEPAD Agency) with funding from the Wellcome Trust [grant #

463 107752/Z/15/Z] and the UK government. MCD was supported by a CIHR CGS-M award.

- 464 MLD and ZLB hold Scholar Awards from MSHR-BC.
- 465

### 466 Authors' contributions

467 SD, ZLB and MAB led the study. YS and HRL coordinated the study. SD and RK

468 quantified T cell responses by flow cytometry. SD, RK, RW, FM, YS, SS, NM-G, MCD,

469 FHO and EB processed specimens and collected data. PKC performed viral neutralization

470 assays. SD, RK, MAB and ZLB analyzed data. RL performed statistical analyses. MLD

471 and MGR supervised SARS-CoV-2 serum antibody quantification. MH, CTC, MH, MH,

472 MGR and JGSM contributed to cohort establishment. ZLB and MAB drafted the

473 manuscript. All authors contributed to manuscript review and editing.

474

### 475 Acknowledgements

476 We thank the leadership and staff of Providence Health Care, St. Paul's Hospital,

477 the BC Centre for Excellence in HIV/AIDS, the Hope to Health Research and Innovation

478 Centre, and Simon Fraser University for supporting this project. In particular, we thank

479 Landon Young and Bruce Ganase for phlebotomy assistance; Laura Burns for technical

480 assistance; Dr Junine Toy, Dr. Chanson Brumme and Paul Sereda for database assistance;

481 and Drs. Silvia Guillemi, Rolando Barrios, Victor Leung, Janet Simons, Daniel Holmes,

482 Curtis Cooper and Aslam Anis for clinical support and guidance. Finally, we thank the

483 participants, without whom this study would not have been possible.

### 484 FIGURE LEGENDS

### 485 Figure 1. SARS-CoV-2 spike-specific T cell responses after COVID-19 vaccination.

486 Panel A: Spike-specific CD4+ T cell frequencies before and after two and three-dose

- 487 COVID-19 vaccination. People living with HIV (PLWH) are in orange; controls without
- 488 HIV (CTRL) are in blue. All participants are COVID-19 naïve. Red bars indicate median
- 489 and IQR. The Mann-Whitney U-test was used for between-group comparisons and the
- 490 Wilcoxon matched pairs test was used for longitudinal paired comparisons. P-values are
- 491 not corrected for multiple comparisons. Panel B: Same as panel A, but for spike-specific
- 492 CD8+ T cell frequencies.
- 493

### 494 Figure 2. Associations between cellular and humoral immune measures after

495 **COVID-19 vaccination.** *Panel A:* Correlation between spike-specific CD4+ and CD8+ T

496 cell frequencies one month after the second dose (open circles) and one month after the

third dose (closed circles) in people living with HIV (PLWH, in orange) and controls

498 without HIV (in blue). *Panel B*: Correlation between spike-specific CD4+ T cell

499 frequencies and SARS-CoV-2 neutralizing antibodies, measured at one month after the

500 second dose (open circles) and one month after the third dose (closed circles) in people

501 living with HIV (PLWH, in orange) and controls without HIV (in blue). All participants
502 are COVID-19 naïve.

503

### 504 Figure 3. Longitudinal SARS-CoV-2 spike-specific immune responses in PLWH

505 who remained naïve or who experienced their first SARS-CoV-2 infection after

506 COVID-19 vaccination. Panel A: SARS-CoV-2 neutralizing antibody titers (reciprocal

507	dilution) in people living with HIV (PLWH) after two, three and four doses of COVID-
508	19 vaccine. Data from the same individual are connected by grey lines. SARS-CoV-2-
509	naïve participants are displayed in orange. SARS-CoV-2 breakthrough participants after
510	the third dose are displayed in green (starting at the point of seroconversion). Note that
511	many antibody titer values overlap, resulting in darker colored symbols. Asterisks denote
512	naive participants who experienced SARS-CoV-2 breakthrough between six months post-
513	dose three and one month post-dose four. Red bars indicate median. The Mann-Whitney
514	U-test was used for between-group comparisons and the Wilcoxon matched pairs test was
515	used for longitudinal paired comparisons. P-values are not corrected for multiple
516	comparisons. <i>Panel B</i> : Same as panel A, but for spike-specific CD4+ T cell responses.
517	Panel C: Same as panels A and B, but for spike-specific CD8+ T cell responses. The
518	Mann-Whitney U-test was used for between-group comparisons and the Wilcoxon
519	matched pairs test was used for longitudinal paired comparisons. P-values are not
520	corrected for multiple comparisons.
521	
522	Figure 4. Analysis of correlates of protection against SARS-CoV-2 breakthrough
523	infection after COVID-19 vaccination. Panel A: Participant ages are shown at study
524	entry, stratified according to those who remained SARS-CoV-2 naive (n=78) and those
525	who experienced SARS-CoV-2 breakthrough infection between one and six months after
526	receiving a third vaccine dose (n=59). PLWH are in orange; controls are in blue. <i>Panel B</i> :
527	Same as panel A, except the frequencies of spike-specific CD4+ T cells one month after

528 three vaccine doses are shown. *Panel C:* Same as panel A and B, except the frequencies

529 of CD8+ T cells one month after three vaccine doses are shown. *Panel D:* Same as other

- 530 panels, except SARS-CoV-2 neutralization activities (reported as reciprocal dilution
- titers) one month after three vaccine doses are shown. For all panels, the Mann-Whitney
- 532 U-test was used to compare groups, using data from the full cohort (all; n=137), from
- 533 controls only (n=87), or from PLWH only (n=50).
- 534

### 535 **REFERENCES**

Boulle A, Davies MA, Hussey H, Ismail M, Morden E, Vundle Z, Zweigenthal V,
 Mahomed H, Paleker M, Pienaar D *et al*: Risk factors for COVID-19 death in a
 population cohort study from the Western Cape Province, South Africa. *Clin Infect Dis* 2020.

540 2. Geretti AM, Stockdale AJ, Kelly SH, Cevik M, Collins S, Waters L, Villa G,

541 Docherty A, Harrison EM, Turtle L *et al*: **Outcomes of COVID-19 related** 

542 hospitalization among people with HIV in the ISARIC WHO Clinical

543 Characterization Protocol (UK): a prospective observational study. *Clin Infect Dis*544 2020.

545 3. Bhaskaran K, Rentsch CT, MacKenna B, Schultze A, Mehrkar A, Bates CJ, Eggo
546 RM, Morton CE, Bacon SCJ, Inglesby P *et al*: HIV infection and COVID-19 death: a

547 population-based cohort analysis of UK primary care data and linked national
548 death registrations within the OpenSAFELY platform. *Lancet HIV* 2021, 8(1):e24-

549 e32.

4. Tesoriero JM, Swain CE, Pierce JL, Zamboni L, Wu M, Holtgrave DR, Gonzalez
CJ, Udo T, Morne JE, Hart-Malloy R *et al*: COVID-19 Outcomes Among Persons
Living With or Without Diagnosed HIV Infection in New York State. *JAMA network open* 2021, 4(2):e2037069.

5. Spinelli MA, Jones BLH, Gandhi M: COVID-19 Outcomes and Risk Factors
Among People Living with HIV. *Curr HIV/AIDS Rep* 2022, 19(5):425-432.

6. Chambers C, Samji H, Cooper CL, Costiniuk CT, Janjua NZ, Kroch AE, Arbess
G, Benoit AC, Buchan SA, Chung H *et al*: Coronavirus disease 2019 vaccine
effectiveness among a population-based cohort of people living with HIV. *AIDS*2022, 36(15):F17-F26.

Fowokan A, Samji H, Puyat JH, Janjua NZ, Wilton J, Wong J, Grennan T,
Chambers C, Kroch A, Costiniuk CT *et al*: Effectiveness of COVID-19 vaccines in
people living with HIV in British Columbia and comparisons with a matched HIVnegative cohort: a test-negative design. *Int J Infect Dis* 2023, 127:162-170.

Madhi SA, Koen AL, Izu A, Fairlie L, Cutland CL, Baillie V, Padayachee SD,
 Dheda K, Barnabas SL, Bhorat QE *et al*: Safety and immunogenicity of the ChAdOx1
 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without
 HIV in South Africa: an interim analysis of a randomised, double-blind, placebo controlled, phase 1B/2A trial. *Lancet HIV* 2021, 8(9):e568-e580.

569 9. Antinori A, Cicalini S, Meschi S, Bordoni V, Lorenzini P, Vergori A, Lanini S,
570 De Pascale L, Matusali G, Mariotti D *et al*: Humoral and Cellular Immune Response
571 Elicited by mRNA Vaccination Against Severe Acute Respiratory Syndrome

572 Coronavirus 2 (SARS-CoV-2) in People Living With Human Immunodeficiency

# 573 Virus Receiving Antiretroviral Therapy Based on Current CD4 T-Lymphocyte 574 Count. Clin Infect Dis 2022, 75(1):e552-e563.

575 10. Brumme ZL, Mwimanzi F, Lapointe HR, Cheung PK, Sang Y, Duncan MC,
576 Yaseen F, Agafitei O, Ennis S, Ng K *et al*: Humoral immune responses to COVID-19
577 vaccination in people living with HIV receiving suppressive antiretroviral therapy.
578 NPJ Vaccines 2022, 7(1):28.

579 11. Jedicke N, Stankov MV, Cossmann A, Dopfer-Jablonka A, Knuth C, Ahrenstorf
580 G, Ramos GM, Behrens GMN: Humoral immune response following prime and boost
581 BNT162b2 vaccination in people living with HIV on antiretroviral therapy. *HIV Med*582 2022, 23(5):558-563.

Lapointe HR, Mwimanzi F, Cheung PK, Sang Y, Yaseen F, Speckmaier S, Barad
E, Moran-Garcia N, Datwani S, Duncan MC *et al*: Antibody response durability
following three-dose COVID-19 vaccination in people with HIV receiving
suppressive ART. *AIDS* 2022.

- 587 13. Lapointe HR, Mwimanzi F, Cheung PK, Sang Y, Yaseen F, Umviligihozo G,
- 588 Kalikawe R, Speckmaier S, Moran-Garcia N, Datwani S et al: People with HIV

receiving suppressive antiretroviral therapy show typical antibody durability after
 dual COVID-19 vaccination, and strong third dose responses. J Infect Dis 2022.

14. Nault L, Marchitto L, Goyette G, Tremblay-Sher D, Fortin C, Martel-Laferrière
V, Trottier B, Richard J, Durand M, Kaufmann D *et al*: Covid-19 vaccine

**immunogenicity in people living with HIV-1**. *Vaccine* 2022, **40**(26):3633-3637.

594 15. Vergori A, Cozzi Lepri A, Cicalini S, Matusali G, Bordoni V, Lanini S, Meschi S,
595 Iannazzo R, Mazzotta V, Colavita F *et al*: Immunogenicity to COVID-19 mRNA
596 vaccine third dose in people living with HIV. *Nat Commun* 2022, 13(1):4922.

597 16. Woldemeskel BA, Karaba AH, Garliss CC, Beck EJ, Wang KH, Laeyendecker O,
598 Cox AL, Blankson JN: The BNT162b2 mRNA Vaccine Elicits Robust Humoral and
599 Cellular Immune Responses in People Living With Human Immunodeficiency Virus
600 (HIV). Clin Infect Dis 2022, 74(7):1268-1270.

- Frater J, Ewer KJ, Ogbe A, Pace M, Adele S, Adland E, Alagaratnam J, Aley PK,
  Ali M, Ansari MA *et al*: Safety and immunogenicity of the ChAdOx1 nCoV-19
  (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of
- a phase 2/3 clinical trial. *Lancet HIV* 2021, **8**(8):e474-e485.
- Fidler S, Fox J, Tipoe T, Longet S, Tipton T, Abeywickrema M, Adele S,
  Alagaratnam J, Ali M, Aley PK *et al*: Booster vaccination against SARS-CoV-2
  induces potent immune responses in people with HIV. *Clin Infect Dis* 2022.

Hensley KS, Jongkees MJ, Geers D, GeurtsvanKessel CH, Mueller YM, Dalm V,
Papageorgiou G, Steggink H, Gorska A, Bogers S *et al*: Immunogenicity and
reactogenicity of SARS-CoV-2 vaccines in people living with HIV in the

## 611 Netherlands: A nationwide prospective cohort study. *PLoS Med* 2022,

612 **19**(10):e1003979.

613 614	20. Hung CY, Hsiao SH, Huang CG, Chang CS, Chen GY, Huang YL, Dutta A, Huang CT: Relatively preserved functional immune capacity with standard COVID
615	<b>19 vaccine regimen in people living with HIV</b> . <i>Front Immunol</i> 2023, <b>14</b> :1204314.
616	21. Sahin U, Muik A, Derhovanessian E, Vogler I, Kranz LM, Vormehr M, Baum A,
617 618	Pascal K, Quandt J, Maurus D <i>et al</i> : <b>COVID-19 vaccine BNT162b1 elicits human</b> <b>antibody and T(H)1 T cell responses</b> . <i>Nature</i> 2020, <b>586</b> (7830):594-599.
619	22. Painter MM, Mathew D, Goel RR, Apostolidis SA, Pattekar A, Kuthuru O, Baxter
620	AE, Herati RS, Oldridge DA, Gouma S <i>et al</i> : <b>Rapid induction of antigen-specific</b>
621	SARS-CoV-2 mRNA vaccination. <i>Immunity</i> 2021, <b>54</b> (9):2133-2142 e2133.
623	23. Matsumoto Y, Murata M, Ohta A, Yamasaki S, Ikezaki H, Toyoda K, Shimono
624	N: The humoral and cellular immune responses following booster vaccination with
626	Chemother 2023.
627	24 Choung DK Langinto HD Song V Ennis S Muvimonzi E Speekmaier S Darad
628	E, Dong W, Liang R, Simons J <i>et al</i> : <b>SARS-CoV-2 live virus neutralization after four</b>
629	COVID-19 vaccine doses in PWH receiving ART. AIDS 2023, Accepted, In Press.
	25 DUA of NACI nonid non-oness Extended dags intervals for COVID 10
630	25. PHAOC: NACI rapid response: Extended dose intervals for COVID-19
630 631	vaccines to optimize early vaccine rollout and population protection in Canada.
630 631 632 633	vaccines to optimize early vaccine rollout and population protection in Canada. <u>https://www.canada.ca/en/public-health/services/immunization/national-advisory-</u> committee-on-immunization-naci/rapid-response-extended-dose-intervals-covid-19-
630 631 632 633 634	25. PHAOC: NACI rapid response: Extended dose intervals for COVID-19 vaccines to optimize early vaccine rollout and population protection in Canada. https://www.canada.ca/en/public-health/services/immunization/national-advisory- committee-on-immunization-naci/rapid-response-extended-dose-intervals-covid-19- vaccines-early-rollout-population-protection.html; 2021.
<ul> <li>630</li> <li>631</li> <li>632</li> <li>633</li> <li>634</li> <li>635</li> </ul>	<ul> <li>25. PHAOC: NACI rapid response: Extended dose intervals for COVID-19 vaccines to optimize early vaccine rollout and population protection in Canada. <a href="https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/rapid-response-extended-dose-intervals-covid-19-vaccines-early-rollout-population-protection.html">https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/rapid-response-extended-dose-intervals-covid-19-vaccines-early-rollout-population-protection.html</a>; 2021.</li> <li>26. Skowronski DM, Febriani Y, Ouakki M, Setayeshgar S, El Adam S, Zou M,</li> </ul>
630 631 632 633 634 635 636	<ul> <li>25. PHAOC: NACI rapid response: Extended dose intervals for COVID-19 vaccines to optimize early vaccine rollout and population protection in Canada. <a href="https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/rapid-response-extended-dose-intervals-covid-19-vaccines-early-rollout-population-protection.html">https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/rapid-response-extended-dose-intervals-covid-19-vaccines-early-rollout-population-protection.html</a>; 2021.</li> <li>26. Skowronski DM, Febriani Y, Ouakki M, Setayeshgar S, El Adam S, Zou M, Talbot D, Prystajecky N, Tyson JR, Gilca R <i>et al</i>: Two-Dose Severe Acute Respiratory</li> </ul>
<ul> <li>630</li> <li>631</li> <li>632</li> <li>633</li> <li>634</li> <li>635</li> <li>636</li> <li>637</li> <li>628</li> </ul>	<ul> <li>25. PHAOC: NACI rapid response: Extended dose intervals for COVID-19 vaccines to optimize early vaccine rollout and population protection in Canada. https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/rapid-response-extended-dose-intervals-covid-19-vaccines-early-rollout-population-protection.html; 2021.</li> <li>26. Skowronski DM, Febriani Y, Ouakki M, Setayeshgar S, El Adam S, Zou M, Talbot D, Prystajecky N, Tyson JR, Gilca R <i>et al</i>: Two-Dose Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Effectiveness With Mixed Schedules and Extended Desing Intervals.</li> </ul>
<ul> <li>630</li> <li>631</li> <li>632</li> <li>633</li> <li>634</li> <li>635</li> <li>636</li> <li>637</li> <li>638</li> <li>639</li> </ul>	<ul> <li>25. PHAOC: NACI rapid response: Extended dose intervals for COVID-19 vaccines to optimize early vaccine rollout and population protection in Canada. https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/rapid-response-extended-dose-intervals-covid-19-vaccines-early-rollout-population-protection.html; 2021.</li> <li>26. Skowronski DM, Febriani Y, Ouakki M, Setayeshgar S, El Adam S, Zou M, Talbot D, Prystajecky N, Tyson JR, Gilca R <i>et al</i>: Two-Dose Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Effectiveness With Mixed Schedules and Extended Dosing Intervals: Test-Negative Design Studies From British Columbia and Ouebec, Canada. <i>Clin Infect Dis</i> 2022, 75(11):1980-1992.</li> </ul>
630 631 632 633 634 635 636 637 638 639	<ul> <li>25. PHAOC: NACI rapid response: Extended dose intervals for COVID-19 vaccines to optimize early vaccine rollout and population protection in Canada. https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/rapid-response-extended-dose-intervals-covid-19-vaccines-early-rollout-population-protection.html; 2021.</li> <li>26. Skowronski DM, Febriani Y, Ouakki M, Setayeshgar S, El Adam S, Zou M, Talbot D, Prystajecky N, Tyson JR, Gilca R <i>et al</i>: Two-Dose Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Effectiveness With Mixed Schedules and Extended Dosing Intervals: Test-Negative Design Studies From British Columbia and Quebec, Canada. <i>Clin Infect Dis</i> 2022, 75(11):1980-1992.</li> </ul>
<ul> <li>630</li> <li>631</li> <li>632</li> <li>633</li> <li>634</li> <li>635</li> <li>636</li> <li>637</li> <li>638</li> <li>639</li> <li>640</li> <li>641</li> </ul>	<ul> <li>25. PHAOC: NACI rapid response: Extended dose intervals for COVID-19 vaccines to optimize early vaccine rollout and population protection in Canada. &lt;a href="https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/rapid-response-extended-dose-intervals-covid-19-vaccines-early-rollout-population-protection.html; 2021.&lt;/a&gt;</li> <li>26. Skowronski DM, Febriani Y, Ouakki M, Setayeshgar S, El Adam S, Zou M, Talbot D, Prystajecky N, Tyson JR, Gilca R <i>et al</i>: Two-Dose Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Effectiveness With Mixed Schedules and Extended Dosing Intervals: Test-Negative Design Studies From British Columbia and Quebec, Canada. <i>Clin Infect Dis</i> 2022, 75(11):1980-1992.</li> <li>27. Buchan SA, Seo CY, Johnson C, Alley S, Kwong JC, Nasreen S, Calzavara A, Lu D, Harris TM, Yu K <i>et al</i>: Enidemiology of Myocarditis and Pericarditis Following</li> </ul>
<ul> <li>630</li> <li>631</li> <li>632</li> <li>633</li> <li>634</li> <li>635</li> <li>636</li> <li>637</li> <li>638</li> <li>639</li> <li>640</li> <li>641</li> <li>642</li> </ul>	<ol> <li>PHAOC: NACI rapid response: Extended dose intervals for COVID-19 vaccines to optimize early vaccine rollout and population protection in Canada. <u>https://www.canada.ca/en/public-health/services/immunization/national-advisory-</u> <u>committee-on-immunization-naci/rapid-response-extended-dose-intervals-covid-19-</u> <u>vaccines-early-rollout-population-protection.html</u>; 2021.</li> <li>Skowronski DM, Febriani Y, Ouakki M, Setayeshgar S, El Adam S, Zou M, Talbot D, Prystajecky N, Tyson JR, Gilca R <i>et al</i>: Two-Dose Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Effectiveness With Mixed Schedules and Extended Dosing Intervals: Test-Negative Design Studies From British Columbia and Quebec, Canada. <i>Clin Infect Dis</i> 2022, 75(11):1980-1992.</li> <li>Buchan SA, Seo CY, Johnson C, Alley S, Kwong JC, Nasreen S, Calzavara A, Lu D, Harris TM, Yu K <i>et al</i>: Epidemiology of Myocarditis and Pericarditis Following mRNA Vaccination by Vaccine Product, Schedule, and Interdose Interval Among</li> </ol>
<ul> <li>630</li> <li>631</li> <li>632</li> <li>633</li> <li>634</li> <li>635</li> <li>636</li> <li>637</li> <li>638</li> <li>639</li> <li>640</li> <li>641</li> <li>642</li> <li>643</li> </ul>	<ul> <li>25. PHAOC: NACI rapid response: Extended dose Intervals for COVID-19</li> <li>vaccines to optimize early vaccine rollout and population protection in Canada. https://www.canada.ca/en/public-health/services/immunization/national-advisory- committee-on-immunization-naci/rapid-response-extended-dose-intervals-covid-19- vaccines-early-rollout-population-protection.html; 2021.</li> <li>26. Skowronski DM, Febriani Y, Ouakki M, Setayeshgar S, El Adam S, Zou M, Talbot D, Prystajecky N, Tyson JR, Gilca R <i>et al</i>: Two-Dose Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Effectiveness With Mixed Schedules and Extended Dosing Intervals: Test-Negative Design Studies From British Columbia and Quebec, Canada. <i>Clin Infect Dis</i> 2022, 75(11):1980-1992.</li> <li>27. Buchan SA, Seo CY, Johnson C, Alley S, Kwong JC, Nasreen S, Calzavara A, Lu D, Harris TM, Yu K <i>et al</i>: Epidemiology of Myocarditis and Pericarditis Following mRNA Vaccination by Vaccine Product, Schedule, and Interdose Interval Among Adolescents and Adults in Ontario, Canada. <i>JAMA Netw Open</i> 2022, 5(6):e2218505.</li> </ul>
<ul> <li>630</li> <li>631</li> <li>632</li> <li>633</li> <li>634</li> <li>635</li> <li>636</li> <li>637</li> <li>638</li> <li>639</li> <li>640</li> <li>641</li> <li>642</li> <li>643</li> <li>644</li> </ul>	<ol> <li>PHAOC: NACI rapid response: Extended dose intervals for COVID-19 vaccines to optimize early vaccine rollout and population protection in Canada. https://www.canada.ca/en/public-health/services/immunization/national-advisory- committee-on-immunization-naci/rapid-response-extended-dose-intervals-covid-19- vaccines-early-rollout-population-protection.html; 2021.</li> <li>Skowronski DM, Febriani Y, Ouakki M, Setayeshgar S, El Adam S, Zou M, Talbot D, Prystajecky N, Tyson JR, Gilca R <i>et al</i>: Two-Dose Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Effectiveness With Mixed Schedules and Extended Dosing Intervals: Test-Negative Design Studies From British Columbia and Quebec, Canada. <i>Clin Infect Dis</i> 2022, 75(11):1980-1992.</li> <li>Buchan SA, Seo CY, Johnson C, Alley S, Kwong JC, Nasreen S, Calzavara A, Lu D, Harris TM, Yu K <i>et al</i>: Epidemiology of Myocarditis and Pericarditis Following mRNA Vaccination by Vaccine Product, Schedule, and Interdose Interval Among Adolescents and Adults in Ontario, Canada. <i>JAMA Netw Open</i> 2022, 5(6):e2218505.</li> <li>Organization WH: Interim recommendations for use of the Moderna mRNA-</li> </ol>
<ul> <li>630</li> <li>631</li> <li>632</li> <li>633</li> <li>634</li> <li>635</li> <li>636</li> <li>637</li> <li>638</li> <li>639</li> <li>640</li> <li>641</li> <li>642</li> <li>643</li> <li>644</li> <li>645</li> </ul>	<ol> <li>PHAOC: NACL rapid response: Extended dose intervals for COVID-19 vaccines to optimize early vaccine rollout and population protection in Canada. https://www.canada.ca/en/public-health/services/immunization/national-advisory- committee-on-immunization-naci/rapid-response-extended-dose-intervals-covid-19- vaccines-early-rollout-population-protection.html; 2021.</li> <li>Skowronski DM, Febriani Y, Ouakki M, Setayeshgar S, El Adam S, Zou M, Talbot D, Prystajecky N, Tyson JR, Gilca R <i>et al</i>: Two-Dose Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Effectiveness With Mixed Schedules and Extended Dosing Intervals: Test-Negative Design Studies From British Columbia and Quebec, Canada. <i>Clin Infect Dis</i> 2022, 75(11):1980-1992.</li> <li>Buchan SA, Seo CY, Johnson C, Alley S, Kwong JC, Nasreen S, Calzavara A, Lu D, Harris TM, Yu K <i>et al</i>: Epidemiology of Myocarditis and Pericarditis Following mRNA Vaccination by Vaccine Product, Schedule, and Interdose Interval Among Adolescents and Adults in Ontario, Canada. <i>JAMA Netw Open</i> 2022, 5(6):e2218505.</li> <li>Organization WH: Interim recommendations for use of the Moderna mRNA- 1273 vaccine against COVID-19. In.; 2021.</li> </ol>
<ul> <li>630</li> <li>631</li> <li>632</li> <li>633</li> <li>634</li> <li>635</li> <li>636</li> <li>637</li> <li>638</li> <li>639</li> <li>640</li> <li>641</li> <li>642</li> <li>643</li> <li>644</li> <li>645</li> <li>646</li> </ul>	<ol> <li>PHAOC: NACL Papid Pesponse: Extended dose Intervals for COVID-19 vaccines to optimize early vaccine rollout and population protection in Canada. https://www.canada.ca/en/public-health/services/immunization/national-advisory- committee-on-immunization-naci/rapid-response-extended-dose-intervals-covid-19- vaccines-early-rollout-population-protection.html; 2021.</li> <li>Skowronski DM, Febriani Y, Ouakki M, Setayeshgar S, El Adam S, Zou M, Talbot D, Prystajecky N, Tyson JR, Gilca R <i>et al</i>: Two-Dose Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Effectiveness With Mixed Schedules and Extended Dosing Intervals: Test-Negative Design Studies From British Columbia and Quebec, Canada. <i>Clin Infect Dis</i> 2022, 75(11):1980-1992.</li> <li>Buchan SA, Seo CY, Johnson C, Alley S, Kwong JC, Nasreen S, Calzavara A, Lu D, Harris TM, Yu K <i>et al</i>: Epidemiology of Myocarditis and Pericarditis Following mRNA Vaccination by Vaccine Product, Schedule, and Interdose Interval Among Adolescents and Adults in Ontario, Canada. <i>JAMA Netw Open</i> 2022, 5(6):e2218505.</li> <li>Organization WH: Interim recommendations for use of the Moderna mRNA- 1273 vaccine against COVID-19. In.; 2021.</li> <li>Weekly update on Variants of Concern [http://www.bccdc.ca/health-</li> </ol>

648 30. Lv Z, Lv S, Li Q, Xia Y, Feng Z, Zhang H, Yang H, Wu Z, Zou N, Mo Q *et al*: A
649 third (booster) dose of the inactivated SARS-CoV-2 vaccine elicits immunogenicity
650 and T follicular helper cell responses in people living with HIV. *Front Immunol* 2023,
651 14:1264160.

Bertoletti A, Le Bert N, Tan AT: SARS-CoV-2-specific T cells in the changing
landscape of the COVID-19 pandemic. *Immunity* 2022, 55(10):1764-1778.

32. Lapuente D, Winkler TH, Tenbusch M: B-cell and antibody responses to
SARS-CoV-2: infection, vaccination, and hybrid immunity. *Cell Mol Immunol* 2024,
21(2):144-158.

33. Murphy TJ, Swail H, Jain J, Anderson M, Awadalla P, Behl L, Brown PE,

658 Charlton CL, Colwill K, Drews SJ *et al*: The evolution of SARS-CoV-2 seroprevalence

659 in Canada: a time-series study, 2020-2023. *CMAJ* 2023, 195(31):E1030-E1037.

660 34. Ahava MJ, Jarva H, Jaaskelainen AJ, Lappalainen M, Vapalahti O, Kurkela S:

661 Rapid increase in SARS-CoV-2 seroprevalence during the emergence of Omicron 662 variant, Finland. *Eur J Clin Microbiol Infect Dis* 2022.

663 35. Clarke KEN, Jones JM, Deng Y, Nycz E, Lee A, Iachan R, Gundlapalli AV, Hall

AJ, MacNeil A: Seroprevalence of Infection-Induced SARS-CoV-2 Antibodies -

665 United States, September 2021-February 2022. MMWR Morb Mortal Wkly Rep 2022,

**666 71**(17):606-608.

<b>Table 1: Participant character</b>	ristics
---------------------------------------	---------

Chavastavistia	PLWH	Controls	
	(n=50)	(n=87)	
Sociodemographic and health variables <sup>a</sup>			
Age in years, median [IQR]	58 [42-65]	50 [35-72]	
Female sex at birth, n (%)	6 (12%)	58 (67%)	
Non-white ethnicity, n (%)	14 (28%)	37 (43%)	
Number of chronic health conditions, median [IQR] <sup>b</sup>	1 [0-1]	0 [0-1]	
HIV plasma viral load (RNA copies per mL)	<50 [<50-<50]	N.A.	
Recent CD4 cell count (per mm <sup>3</sup> ), median [IQR]	695 [468-983]	N.A.	
Nadir CD4 cell count (per mm <sup>3</sup> ), median [IQR]	250 [140-490]	N.A.	
Vaccine details			
Initial regimen <sup>c</sup>			
mRNA only, n (%)	42 (84%)	84 (97%)	
ChAdOx1-containing, n (%)	8 (16%)	3 (3%)	
Third dose			
BNT162b2, n (%)	17 (34%)	34 (39%)	
mRNA-1273, n (%)	33 (66%)	53 (61%)	
Days between first and second doses, median [IQR]	59 [53-68]	89 [73-98]	
Days between second and third doses, median [IQR]	182 [141-191]	197 [169-215]	
Post-3rd vaccine dose SARS-CoV-2 infections, n (%) <sup>d</sup>	21 (42%)	38 (44%)	

<sup>a</sup>Sociodemographic, health, and vaccine data were collected by self-report and confirmed through medical records where available. CD4+ T cell counts and HIV plasma viral loads were obtained from medical records.

<sup>b</sup>Chronic conditions were defined as hypertension, diabetes, asthma, obesity, chronic diseases of lung, liver, kidney, heart or blood, cancer, and immunosuppression due to chronic conditions or medication.

<sup>c</sup>Initial regimen refers to the first two doses. "mRNA only" refers to participants who received BNT162b2 and/or mRNA-1273 while "ChAdOx1-containing" refers to participants who received two ChAdOx1 doses, or one ChAdOx1 dose plus one mRNA dose.

<sup>d</sup>SARS-CoV-2 infections that occurred between one and six months after the third vaccine dose.







PLWH who remained COVID-19 naive until at least 6 months after 3rd dose PLWH who acquired SARS-CoV-2 infection btw 1 and 6 months after 3rd dose



PLWH who remained COVID-19 naive until at least 6 months after 3rd dose PLWH who acquired SARS-CoV-2 infection btw 1 and 6 months after 3rd dose



until at least 6 months after 3rd dose

PLWH who acquired SARS-CoV-2 infection btw 1 and 6 months after 3rd dose



Outcome btw 1 and 6 months after 3rd dose

Outcome btw 1 and 6 months after 3rd dose

	Outcome measures						
Variable	% Spike- after	responsive CD • two vaccine d	% Spike-responsive CD4+ T cells after three vaccine doses				
vailaute	Estimate	Standard error	P value	Estimate	Standard error	P value	
PLWH group	-0.29	0.17	0.08	-0.06	0.10	0.58	
Age (per year)	0.001	0.004	0.83	-0.004	0.002	0.08	
Male sex	0.13	0.14	0.38	0.24	0.084	0.0044	
White ethnicity	-0.19	0.14	0.16	-0.045	0.076	0.55	
Health conditions (per condition) <sup>a</sup>	-0.03	0.08	0.72	0.11	0.047	0.022	
ChAdOx1-containing initial vaccine regimen <sup>b</sup>	0.37	0.21	0.09	0.14	0.12	0.27	
Days between 1st and 2nd vaccine dose (per day)	0.005	0.003	0.12	0.002	0.002	0.30	
mRNA-1273 as third vaccine dose <sup>c</sup>	N.A.	N.A.	N.A.	0.17	0.077	0.033	
Days between 2nd and 3rd vaccine dose (per day)	N.A.	N.A.	N.A.	0.001	0.001	0.47	
% Spike specific T cells after two doses (per 1% increment)	N.A.	N.A.	N.A.	0.71	0.058	$<2x10^{-16}$	

TABLE S1. Multivariable zero-inflated beta regressions exploring the relationship between sociodemographic, health and vaccine-related variables on Spike-specific CD4+ T cell responses following two and three COVID-19 vaccine doses

<sup>a</sup>Continuous variable, defined as: chronic blood disorder, cancer, hypertension, diabetes, asthma, obesity (body mass index ≥30), chronic diseases of lung, liver, kidney or heart "Binary variable, defined as two doses of ChAdOx1, or a heterologous regimen consisting of one dose each of ChAdOx1 and an mRNA vaccine

(mRNA-1273 or BNT162b2) (vs. a reference group defined as two doses of mRNA vaccine)

 $^\circ$ Binary variable, defined as a third dose of mRNA-1273 (vs. a reference group defined as a third dose of BNT162b2)

	Outcome measures					
Variable	% Spike-r after	esponsive CD two vaccine d	98+ T cells Ioses	% Spike-responsive CD8+ T cells after three vaccine doses		
variable	Estimate	Standard error	P value	Estimate	Standard error	P value
PLWH group	-0.0002	0.16	0.99	-0.24	0.12	0.045
Age (per year)	-0.001	0.004	0.87	0.001	0.004	0.87
Male sex	0.18	0.14	0.20	0.11	0.10	0.24
White ethnicity	0.14	0.13	0.30	-0.01	0.08	0.90
Health conditions (per condition) <sup>a</sup>	-0.02	0.08	0.75	-0.05	0.06	0.37
ChAdOx1-containing initial vaccine regimen <sup>b</sup>	0.39	0.20	0.049	0.22	0.14	0.12
Days between 1st and 2nd vaccine dose (per day)	0.002	0.003	0.54	0.00	0.00	0.16
mRNA-1273 as third vaccine dose <sup>c</sup>	N.A.	N.A.	N.A.	0.02	0.11	0.86
Days between 2nd and 3rd vaccine dose (per day)	N.A.	N.A.	N.A.	-0.001	0.002	0.43
% Snike specific T cells after two doses (per 1% increment)	N A	N A	N A	0 70	0.07	<20-16

TABLE S2. Multivariable zero-inflated beta regressions exploring the relationship between sociodemographic, health and vaccine-related variables on Spike-specific CD8+ T cell responses following two and three COVID-19 vaccine doses

<sup>a</sup>Continuous variable, defined as: chronic blood disorder, cancer, hypertension, diabetes, asthma, obesity (body mass index ≥30), chronic diseases of lung, liver, kidney or heart

<sup>o</sup>Binary variable, defined as two doses of ChAdOx1, or a heterologous regimen consisting of one dose each of ChAdOx1 and an mRNA vaccine (mRNA-1273 or BNT162b2) (vs. a reference group defined as two doses of mRNA vaccine)

<sup>c</sup>Binary variable, defined as a third dose of mRNA-1273 (vs. a reference group defined as a third dose of BNT162b2)

Variables	Estimate	95% CI	P value
PLWH group	0.93	0.30 to 2.78	0.89
Age (per year)	0.96	0.93 to 0.98	0.002
Male sex	0.68	0.27 to 1.66	0.40
White ethnicity	1.55	0.69 to 3.60	0.29
Health conditions (per condition) <sup>a</sup>	1.22	0.72 to 2.09	0.46
ChAdOx1-containing initial vaccine regimen <sup>b</sup>	2.02	0.52 to 8.27	0.31
Days between 1st and 2nd vaccine dose (per day)	1.00	0.97 to 1.02	0.76
mRNA-1273 as third vaccine dose <sup>c</sup>	1.09	0.49 to 2.47	0.84
Days between 2nd and 3rd vaccine dose (per day)	1.00	0.99 to 1.01	0.96
% Spike specific CD4+ T cells after three doses (per 1% increment)	0.76	0.25 to 2.13	0.61
% Spike specific CD8+ T cells after two doses (per 1% increment)	0.86	0.36 to 2.01	0.73
Virus neutralizing activirty (per 1% increment)	1.00	0.99 to 1.00	0.26

TABLE S3. Multivariable logistic regression looking at factors associated with risk of first breakthrough infection between
1 and 6 months following receipt of the 3rd COVID-19 vaccine dose

<sup>a</sup>Continuous variable, defined as: chronic blood disorder, cancer, hypertension, diabetes, asthma, obesity (body mass index ≥30), chronic diseases of lung, liver, kidney or heart

<sup>®</sup>Binary variable, defined as two doses of ChAdOx1, or a heterologous regimen consisting of one dose each of ChAdOx1 and an mRNA vaccine (mRNA-1273 or BNT162b2) (vs. a reference group defined as two doses of mRNA vaccine)

<sup>°</sup>Binary variable, defined as a third dose of mRNA-1273 (vs. a reference group defined as a third dose of BNT162b2)



Figure S1. Gating strategy used to quantify vaccine-induced spike-specific T cell responses by flow cytometry.



Figure S2. Correlations between vaccine-induced spike-specific T cell responses and recent or nadir CD4 cell count in PLWH.